Charles Schwab
ANTX icon

Charles Schwab’s AN2 Therapeutics ANTX Stock Holding History

Charles Schwab’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Buy
+64,220
New +$276K ﹤0.01% 3327
2023
Q2 		– Sell
-29,898
Closed -$295K – 3615
2023
Q1 		$295K Buy
29,898
+5,000
+20% +$55.6K ﹤0.01% 3094
2022
Q4 		$237K Buy
24,898
+14,709
+144% +$197K ﹤0.01% 3154
2022
Q3 		$178K Hold
10,189
– – ﹤0.01% 3177
2022
Q2 		$79K Buy
+10,189
New +$135K ﹤0.01% 3308

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Charles Schwab's ANTX Position: Q2 2026 in Review

Charles Schwab opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 64,220 shares worth $311K. The stake represents ﹤0.01% of the portfolio and ranks #3327 among its holdings. This is a return to the name: Charles Schwab previously reported a position in ANTX as recently as Q1 2023.

Charles Schwab first reported a position in ANTX in Q2 2022 and has held it in 5 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Charles Schwab held 64,220 shares of AN2 Therapeutics worth $311K as of Q2 2026.
  • AN2 Therapeutics was a new Charles Schwab position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3327 holding.
  • Charles Schwab first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.